Ledipasvir/sofosbuvir: the fixed dose combination in the new era of treatment for HCV

Reviews in Health Care

View Publication Info
Field Value
Title Ledipasvir/sofosbuvir: the fixed dose combination in the new era of treatment for HCV
Creator Ciancio, Alessia
Ledipasvir; Sofosbuvir; HCV
Description Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications, other reasons for ineligibility and side-effects. The fixed dosed combination ledipasvir/sofosbuvir (LDV / SOF) is the first approved regimen that doesn’t require administration with interferon or ribavirin. LDV / SOF is also the first single-pill approved for the treatment of chronic HCV genotype 1 in both treatment-naïve and treatment-experienced patients. The results of the phase III studies demonstrate the combination has been very well tolerated and SVR rates consistently above 90%. Objective of this review is to present clinical evidence of efficacy and safety of the combination LDV / SOF in different subgroups of patients with HCV.
Publisher SEEd
Date 2015-07-30
Type info:eu-repo/semantics/article

Format text/html
Identifier https://journals.edizioniseed.it/index.php/rhc/article/view/1178
Source Reviews in Health Care; Vol 6, No 3 (2015); 87-98
Language eng
Relation https://journals.edizioniseed.it/index.php/rhc/article/view/1178/1443

Rights Copyright (c) 2015 Seed

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us


Copyright © 2015-2018 Simon Fraser University Library